Browse the latest SEC filings and forms submitted by ASTRAZENECA PLC (AZN). Access annual reports, quarterly statements, and other official disclosures.
View Insider Transactions for ASTRAZENECA PLC (AZN).
Search Company Filings →| Form | Filing Date | Description | Link |
|---|---|---|---|
| 6-K | May 18, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 18, 2026 | ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS | View Document |
| 6-K | May 18, 2026 | BAXFENDY APPROVED IN THE US FOR HYPERTENSION | View Document |
| 6-K | May 14, 2026 | IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER | View Document |
| 4 | May 8, 2026 | OWNERSHIP DOCUMENT | View Document |
| 6-K | May 1, 2026 | FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER | View Document |
| 6-K | May 1, 2026 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | View Document |
| 6-K | May 1, 2026 | FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER | View Document |
| 6-K | April 29, 2026 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 28, 2026 | BREZTRI APPROVED IN THE US FOR ASTHMA | View Document |
| SCHEDULE 13G | April 28, 2026 | - | View Document |
| 6-K | April 27, 2026 | SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US | View Document |
| 6-K | April 23, 2026 | DIRECTORATE CHANGE | View Document |
| 6-K | April 21, 2026 | I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT | View Document |
| 6-K | April 20, 2026 | THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD | View Document |
| 6-K | April 9, 2026 | RESULT OF AGM | View Document |
| 25-NSE | April 8, 2026 | - | View Document |
| 6-K | April 2, 2026 | IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER | View Document |
| 6-K | April 1, 2026 | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | View Document |
| 6-K | March 31, 2026 | EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS | View Document |
| 6-K | March 27, 2026 | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS | View Document |
| 6-K | March 20, 2026 | NOTIFICATION OF ADMISSION OF SHARES | View Document |
| 3 | March 19, 2026 | OWNERSHIP DOCUMENT | View Document |
| 6-K | March 16, 2026 | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER | View Document |
| 6-K | March 10, 2026 | NOTICE OF AGM | View Document |
| 6-K | March 10, 2026 | FORM 6-K | View Document |
| 6-K | March 6, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| CERT | March 4, 2026 | NYSE CERTIFICATION | View Document |
| 8-A12B | March 3, 2026 | FORM 8-A12B | View Document |
| 6-K | March 2, 2026 | FORM 6-K | View Document |
| 6-K | March 2, 2026 | TOTAL VOTING RIGHTS | View Document |
| 424B2 | Feb. 27, 2026 | 424B2 | View Document |
| FWP | Feb. 26, 2026 | FWP | View Document |
| 6-K | Feb. 26, 2026 | ASTRAZENECA PRICES A $2BN BOND OFFERING | View Document |
| 424B2 | Feb. 25, 2026 | 424B2 | View Document |
| 6-K | Feb. 25, 2026 | FILING OF FORM 20-F WITH SEC | View Document |
| 6-K | Feb. 24, 2026 | DIRECTORATE CHANGE | View Document |
| 6-K | Feb. 24, 2026 | FORM 6-K | View Document |
| 20-F | Feb. 24, 2026 | 20-F | View Document |
| IRANNOTICE | Feb. 24, 2026 | IRANNOTICE | View Document |
| 6-K | Feb. 24, 2026 | ANNUAL FINANCIAL REPORT | View Document |
| 6-K | Feb. 20, 2026 | FIXED-DURATION CALQUENCE COMBO APPROVED IN US | View Document |
| 6-K | Feb. 10, 2026 | FINAL RESULTS | View Document |
| 6-K | Feb. 3, 2026 | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | View Document |
| 6-K | Feb. 2, 2026 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 2, 2026 | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | View Document |
| 6-K | Feb. 2, 2026 | ASTRAZENECA BEGINS TRADING ON NYSE | View Document |
| S-8 | Feb. 2, 2026 | FORM S-8 | View Document |
| 25 | Jan. 30, 2026 | FORM 25 | View Document |
| 6-K | Jan. 30, 2026 | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | View Document |
| 6-K | Jan. 29, 2026 | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | View Document |
| CERT | Jan. 22, 2026 | NYSE CERTIFICATION | View Document |
| CERT | Jan. 22, 2026 | NYSE CERTIFICATION | View Document |
| 8-A12B | Jan. 22, 2026 | 8-A12B | View Document |
| 8-A12B | Jan. 22, 2026 | 8-A12B | View Document |
| 6-K | Jan. 20, 2026 | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | View Document |
| 6-K | Jan. 8, 2026 | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | View Document |
| 6-K | Jan. 2, 2026 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 22, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 22, 2025 | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | View Document |
| 6-K | Dec. 22, 2025 | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | View Document |
| 6-K | Dec. 19, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 16, 2025 | SUBCUTANEOUS SAPHNELO APPROVED IN EU | View Document |
| 6-K | Dec. 16, 2025 | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | View Document |
| 6-K | Dec. 4, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Dec. 1, 2025 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 26, 2025 | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | View Document |
| 6-K | Nov. 24, 2025 | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | View Document |
| 6-K | Nov. 20, 2025 | KOSELUGO (SELUMETINIB) APPROVED IN THE US | View Document |
| 6-K | Nov. 17, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Nov. 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 25-NSE | Nov. 14, 2025 | - | View Document |
| 144 | Nov. 12, 2025 | - | View Document |
| 6-K | Nov. 10, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 6, 2025 | 9M AND Q3 2025 RESULTS | View Document |
| 6-K | Nov. 3, 2025 | RESULT OF GENERAL MEETING | View Document |
| 6-K | Nov. 3, 2025 | FORM 6-K | View Document |
| 6-K | Nov. 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 28, 2025 | DIRECTOR DECLARATION | View Document |
| 6-K | Oct. 28, 2025 | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | View Document |
| 6-K | Oct. 22, 2025 | TEZSPIRE APPROVED IN EU FOR CRSWNP | View Document |
| 6-K | Oct. 20, 2025 | US FDA APPROVES TEZSPIRE IN CRSWNP | View Document |
| 6-K | Oct. 20, 2025 | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | View Document |
| 6-K | Oct. 14, 2025 | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | View Document |
| 6-K | Oct. 7, 2025 | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | View Document |
| 6-K | Oct. 6, 2025 | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | View Document |
| 6-K | Oct. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 29, 2025 | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | View Document |
| 6-K | Sept. 29, 2025 | AZN HARMONISES LISTING STRUCTURE | View Document |
| 6-K | Sept. 29, 2025 | 6-K | View Document |
| 6-K | Sept. 25, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 22, 2025 | KOSELUGO RECOMMENDED FOR EU APPROVAL | View Document |
| 6-K | Sept. 22, 2025 | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | View Document |
| 6-K | Sept. 17, 2025 | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | View Document |
| 6-K | Sept. 17, 2025 | UPDATE ON RESOLUTE PHASE III TRIAL | View Document |
| 6-K | Sept. 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 28, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 26, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 21, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 18, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 15, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 12, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 29, 2025 | FORM 6-K | View Document |
| 6-K | July 24, 2025 | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | View Document |
| 6-K | July 22, 2025 | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | View Document |
| 6-K | July 16, 2025 | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | View Document |
| 6-K | July 14, 2025 | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | View Document |
| 6-K | July 7, 2025 | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | View Document |
| 6-K | July 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 11-K | June 26, 2025 | FORM 11-K | View Document |
| 6-K | June 24, 2025 | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | View Document |
| 6-K | June 13, 2025 | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | View Document |
| 6-K | June 12, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 6, 2025 | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | View Document |
| 6-K | June 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 2, 2025 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 27, 2025 | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | View Document |
| 6-K | May 23, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 21, 2025 | DIRECTOR DECLARATION | View Document |
| 6-K | May 20, 2025 | ACQUISITION OF ESOBIOTEC COMPLETED | View Document |
| 6-K | May 9, 2025 | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | View Document |
| 6-K | May 7, 2025 | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | View Document |
| 6-K | May 6, 2025 | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | View Document |
| 6-K | May 2, 2025 | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | View Document |
| 6-K | May 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 1, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 29, 2025 | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | View Document |
| 6-K | April 29, 2025 | UPDATE ON CAPITELLO-280 PHASE III TRIAL | View Document |
| 6-K | April 29, 2025 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 22, 2025 | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | View Document |
| 6-K | April 11, 2025 | RESULT OF AGM | View Document |
| SCHEDULE 13G/A | April 10, 2025 | - | View Document |
| 6-K | April 4, 2025 | IMFINZI APPROVED IN EU FOR AEGEAN | View Document |
| 6-K | April 4, 2025 | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | View Document |
| 6-K | April 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 31, 2025 | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | View Document |
| 6-K | March 31, 2025 | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | View Document |
| 6-K | March 21, 2025 | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | View Document |
| 6-K | March 17, 2025 | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | View Document |
| 6-K | March 17, 2025 | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | March 17, 2025 | ASTRAZENECA TO ACQUIRE ESOBIOTEC | View Document |
| 6-K | March 12, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | March 7, 2025 | FORM 6-K | View Document |
| 6-K | March 7, 2025 | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | View Document |
| 6-K | March 7, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 7, 2025 | NOTICE OF AGM | View Document |
| 6-K | March 6, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 5, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 3, 2025 | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | View Document |
| 6-K | March 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 28, 2025 | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | View Document |
| 6-K | Feb. 26, 2025 | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | View Document |
| 6-K | Feb. 19, 2025 | FILING OF FORM 20-F WITH SEC | View Document |
| 6-K | Feb. 18, 2025 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Feb. 18, 2025 | ANNUAL FINANCIAL REPORT | View Document |
| 6-K | Feb. 18, 2025 | DIRECTORATE CHANGE | View Document |
| 6-K | Feb. 18, 2025 | FORM 6-K | View Document |
| IRANNOTICE | Feb. 18, 2025 | IRANNOTICE | View Document |
| 20-F | Feb. 18, 2025 | FORM 20-F | View Document |
| 6-K | Feb. 6, 2025 | FINAL RESULTS | View Document |
| EFFECT | Feb. 5, 2025 | - | View Document |
| 6-K | Feb. 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 3, 2025 | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | View Document |
| 6-K | Jan. 28, 2025 | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | View Document |
| F-6 | Jan. 21, 2025 | - | View Document |
| 6-K | Jan. 21, 2025 | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | View Document |
| 6-K | Jan. 17, 2025 | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | View Document |
| 6-K | Jan. 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 26, 2024 | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | View Document |
| 6-K | Dec. 23, 2024 | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | View Document |
| 6-K | Dec. 16, 2024 | DIRECTORATE CHANGE | View Document |
| 6-K | Dec. 5, 2024 | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | View Document |
| 6-K | Dec. 4, 2024 | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | View Document |
| 6-K | Dec. 2, 2024 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 25, 2024 | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | View Document |
| 6-K | Nov. 20, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 18, 2024 | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | View Document |
| 6-K | Nov. 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 12, 2024 | ASTRAZENECA INVESTS $3.5 BILLION IN US | View Document |
| 6-K | Nov. 12, 2024 | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Nov. 12, 2024 | 9M AND Q3 2024 RESULTS | View Document |
| 6-K | Nov. 12, 2024 | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | View Document |
| 6-K | Nov. 8, 2024 | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | View Document |
| 6-K | Nov. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 30, 2024 | AZN CHINA PRESIDENT UNDER INVESTIGATION | View Document |
| SC 13G | Oct. 28, 2024 | SC 13G | View Document |
| 6-K | Oct. 21, 2024 | FORM 6-K | View Document |
| SC 13G | Oct. 11, 2024 | SC 13G | View Document |
| 6-K | Oct. 7, 2024 | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | View Document |
| 6-K | Oct. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 26, 2024 | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | View Document |
| 6-K | Sept. 23, 2024 | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | View Document |
| 6-K | Sept. 23, 2024 | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | View Document |
| 6-K | Sept. 20, 2024 | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | View Document |
| 6-K | Sept. 18, 2024 | FASENRA EGPA US FDA APPROVAL | View Document |
| 6-K | Sept. 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 3, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 16, 2024 | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | View Document |
| 6-K | Aug. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 30, 2024 | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | View Document |
| 6-K | July 29, 2024 | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | View Document |
| 6-K | July 26, 2024 | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | View Document |
| 6-K | July 25, 2024 | FORM 6K | View Document |
| 6-K | July 15, 2024 | ACQUISITION OF AMOLYT PHARMA COMPLETED | View Document |
| 6-K | July 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 1, 2024 | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | View Document |
| 11-K | June 26, 2024 | ANNUAL REPORT | View Document |
| 6-K | June 25, 2024 | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | View Document |
| 6-K | June 25, 2024 | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | View Document |
| 6-K | June 18, 2024 | UPDATE ON CAPITELLO-290 PHASE III TRIAL | View Document |
| 6-K | June 17, 2024 | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | View Document |
| 6-K | June 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 4, 2024 | FORM 6-K | View Document |
| 25-NSE | June 4, 2024 | - | View Document |
| 6-K | June 3, 2024 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | June 3, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 3, 2024 | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | View Document |
| 6-K | May 28, 2024 | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | View Document |
| 6-K | May 21, 2024 | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | View Document |
| 6-K | May 20, 2024 | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | View Document |
| 6-K | May 16, 2024 | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | View Document |
| 6-K | May 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 7, 2024 | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | View Document |
| 6-K | May 2, 2024 | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | View Document |
| 6-K | May 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 29, 2024 | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | View Document |
| 6-K | April 29, 2024 | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | View Document |
| 6-K | April 25, 2024 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 11, 2024 | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | View Document |
| 6-K | April 11, 2024 | RESULT OF AGM | View Document |
| 6-K | April 8, 2024 | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS | View Document |
| 6-K | April 5, 2024 | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC | View Document |
| 6-K | April 2, 2024 | VOYDEYA APPROVED IN US | View Document |
| 6-K | April 2, 2024 | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER | View Document |
| 6-K | April 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 25, 2024 | ULTOMIRIS APPROVED IN THE US FOR NMOSD | View Document |
| 6-K | March 19, 2024 | FORM 6-K | View Document |
| F-3ASR | March 19, 2024 | F-3ASR | View Document |
| DFAN14A | March 19, 2024 | DFAN14A | View Document |
| 6-K | March 14, 2024 | ASTRAZENECA TO ACQUIRE AMOLYT | View Document |
| 6-K | March 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 7, 2024 | FORM 6-K | View Document |
| 6-K | March 7, 2024 | NOTICE OF AGM | View Document |
| 6-K | March 6, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| CERT | March 6, 2024 | - | View Document |
| 8-A12B | March 5, 2024 | 8-A12B | View Document |
| 6-K | March 4, 2024 | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | View Document |
| 6-K | March 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 26, 2024 | FORM 6-K | View Document |
| 6-K | Feb. 26, 2024 | VOYDEYA RECOMMENDED FOR EU APPROVAL | View Document |
| 424B2 | Feb. 23, 2024 | 424B2 | View Document |
| 6-K | Feb. 22, 2024 | FORM 6-K | View Document |
| 6-K | Feb. 22, 2024 | ASTRAZENECA PRICES A $5BN BOND OFFERING | View Document |
| 6-K | Feb. 22, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| FWP | Feb. 22, 2024 | FWP | View Document |
| 424B2 | Feb. 21, 2024 | 424B2 | View Document |
| 6-K | Feb. 21, 2024 | FILING OF FORM 20-F WITH SEC | View Document |
| SC TO-T/A | Feb. 21, 2024 | SC TO-T/A | View Document |
| 6-K | Feb. 20, 2024 | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | View Document |
| S-8 | Feb. 20, 2024 | FORM S-8 | View Document |
| IRANNOTICE | Feb. 20, 2024 | IRANNOTICE | View Document |
| 20-F | Feb. 20, 2024 | FORM 20-F | View Document |
| 6-K | Feb. 20, 2024 | FORM 6-K | View Document |
| 6-K | Feb. 20, 2024 | ANNUAL FINANCIAL REPORT | View Document |
| SC TO-T/A | Feb. 20, 2024 | SC TO-T/A | View Document |
| 6-K | Feb. 20, 2024 | FORM 6-K | View Document |
| 6-K | Feb. 20, 2024 | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | View Document |
| 6-K | Feb. 20, 2024 | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | View Document |
| 6-K | Feb. 20, 2024 | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | View Document |
| SC TO-T/A | Feb. 15, 2024 | SC TO-T/A | View Document |
| 6-K | Feb. 8, 2024 | FINAL RESULTS | View Document |
| 6-K | Feb. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| SC 13G/A | Jan. 24, 2024 | - | View Document |
| 6-K | Jan. 19, 2024 | FORM 6-K | View Document |
| SC TO-T/A | Jan. 19, 2024 | SC TO-T/A | View Document |
| SC TO-T/A | Jan. 11, 2024 | SC TO-T/A | View Document |
| CORRESP | Jan. 10, 2024 | - | View Document |
| 6-K | Jan. 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 27, 2023 | ASTRAZENECA ACQUIRES GRACELL | View Document |
| SC TO-T | Dec. 27, 2023 | SC TO-T | View Document |
| 6-K | Dec. 26, 2023 | FORM 6-K | View Document |
| 6-K | Dec. 22, 2023 | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | View Document |
| 6-K | Dec. 14, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 12, 2023 | FORM 6-K | View Document |
| SC TO-C | Dec. 12, 2023 | SC TO-C | View Document |
| 6-K | Dec. 12, 2023 | ASTRAZENECA TO ACQUIRE ICOSAVAX | View Document |
| 6-K | Dec. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 1, 2023 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 1, 2023 | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | View Document |
| 6-K | Nov. 24, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 17, 2023 | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | View Document |
| 25-NSE | Nov. 14, 2023 | - | View Document |
| 6-K | Nov. 14, 2023 | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | View Document |
| 144 | Nov. 13, 2023 | - | View Document |
| 6-K | Nov. 9, 2023 | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | View Document |
| 6-K | Nov. 9, 2023 | 9M AND Q3 2023 RESULTS | View Document |
| 6-K | Nov. 9, 2023 | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | View Document |
| 6-K | Nov. 9, 2023 | DIRECTOR DECLARATION | View Document |
| 6-K | Nov. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 1, 2023 | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | View Document |
| 6-K | Oct. 3, 2023 | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | View Document |
| 6-K | Oct. 2, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 25, 2023 | DATO-DXD IMPROVED PFS IN BREAST CANCER | View Document |
| 6-K | Sept. 20, 2023 | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | View Document |
| 6-K | Sept. 15, 2023 | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | View Document |
| 6-K | Sept. 11, 2023 | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Sept. 6, 2023 | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | View Document |
| 6-K | Sept. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 25-NSE | Aug. 16, 2023 | - | View Document |
| 6-K | Aug. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 28, 2023 | FORM 6K | View Document |
| 6-K | July 28, 2023 | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER | View Document |
| 6-K | July 17, 2023 | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION | View Document |
| 6-K | July 3, 2023 | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER | View Document |
| 6-K | July 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 11-K | June 28, 2023 | ANNUAL REPORT | View Document |
| 6-K | June 9, 2023 | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION | View Document |
| 6-K | June 9, 2023 | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS | View Document |
| 6-K | June 2, 2023 | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS | View Document |
| 6-K | June 1, 2023 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | June 1, 2023 | LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER | View Document |
| 6-K | June 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 26, 2023 | IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER | View Document |
| 25-NSE | May 25, 2023 | - | View Document |
| 6-K | May 22, 2023 | DIRECTORATE CHANGE | View Document |
| 6-K | May 17, 2023 | TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER | View Document |
| 6-K | May 9, 2023 | FARXIGA EXTENDED IN THE US FOR HEART FAILURE | View Document |
| 6-K | May 9, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 2, 2023 | ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER | View Document |
| 6-K | May 2, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 2, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 27, 2023 | BOARD COMMITTEE CHANGES | View Document |
| 6-K | April 27, 2023 | FORM 6-K | View Document |
| 6-K | April 27, 2023 | RESULT OF AGM | View Document |
| 6-K | April 27, 2023 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 26, 2023 | DIRECTOR DECLARATION | View Document |
| 6-K | April 11, 2023 | UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI | View Document |
| 6-K | April 5, 2023 | LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER | View Document |
| 6-K | April 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 3, 2023 | ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL | View Document |
| 6-K | March 30, 2023 | ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 | View Document |
| 6-K | March 27, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 22, 2023 | NOTICE OF AGM | View Document |
| 6-K | March 22, 2023 | FORM 6-K | View Document |
| CERT | March 15, 2023 | - | View Document |
| 8-A12B | March 13, 2023 | 8-A12B | View Document |
| 6-K | March 9, 2023 | IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER | View Document |
| 6-K | March 8, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 8, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2023 | ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS | View Document |
| 6-K | March 3, 2023 | FORM 6-K | View Document |
| 424B2 | March 2, 2023 | 424B2 | View Document |
| 6-K | March 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 1, 2023 | ASTRAZENECA PRICES A $2.25BN BOND OFFERING | View Document |
| FWP | March 1, 2023 | FWP | View Document |
| 424B2 | Feb. 28, 2023 | 424B2 | View Document |
| SC TO-T/A | Feb. 24, 2023 | SC TO-T/A | View Document |
| 6-K | Feb. 24, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 24, 2023 | ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET | View Document |
| 6-K | Feb. 24, 2023 | ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING | View Document |
| 6-K | Feb. 23, 2023 | ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 | View Document |
| SC TO-T/A | Feb. 23, 2023 | SC TO-T | View Document |
| 6-K | Feb. 22, 2023 | FILING OF FORM 20-F WITH SEC | View Document |
| 6-K | Feb. 21, 2023 | FORM 6-K | View Document |
| IRANNOTICE | Feb. 21, 2023 | IRANNOTICE | View Document |
| 20-F | Feb. 21, 2023 | FORM 20-F | View Document |
| 6-K | Feb. 21, 2023 | ANNUAL FINANCIAL REPORT | View Document |
| 6-K | Feb. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 9, 2023 | FINAL RESULTS | View Document |
| SC TO-T/A | Feb. 3, 2023 | SC TO-T/A | View Document |
| 6-K | Feb. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 26, 2023 | UPDATE ON EVUSHELD US EUA | View Document |
| SC 13G/A | Jan. 24, 2023 | - | View Document |
| SC TO-T | Jan. 23, 2023 | SC TO-T | View Document |
| 6-K | Jan. 17, 2023 | ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED | View Document |
| 6-K | Jan. 11, 2023 | AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA | View Document |
| SC TO-C | Jan. 9, 2023 | SC TO-C | View Document |
| 6-K | Jan. 9, 2023 | ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET | View Document |
| 6-K | Jan. 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 30, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 28, 2022 | IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS | View Document |
| 6-K | Dec. 28, 2022 | CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL | View Document |
| 6-K | Dec. 21, 2022 | LYNPARZA APPROVED IN EU FOR PROSTATE CANCER | View Document |
| 6-K | Dec. 21, 2022 | IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER | View Document |
| 6-K | Dec. 19, 2022 | ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME | View Document |
| 6-K | Dec. 19, 2022 | ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD | View Document |
| 6-K | Dec. 19, 2022 | FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF | View Document |
| 6-K | Dec. 19, 2022 | UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL | View Document |
| 6-K | Dec. 19, 2022 | IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT | View Document |
| 6-K | Dec. 15, 2022 | UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA | View Document |
| 6-K | Dec. 8, 2022 | CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER | View Document |
| 6-K | Dec. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 1, 2022 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 30, 2022 | ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE | View Document |
| 6-K | Nov. 29, 2022 | ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS | View Document |
| 6-K | Nov. 23, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 14, 2022 | ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC | View Document |
| 6-K | Nov. 14, 2022 | IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER | View Document |
| 6-K | Nov. 14, 2022 | LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC | View Document |
| 6-K | Nov. 14, 2022 | IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC | View Document |
| 6-K | Nov. 10, 2022 | YTD AND Q3 2022 RESULTS | View Document |
| 6-K | Nov. 9, 2022 | FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA | View Document |
| 6-K | Nov. 4, 2022 | BEYFORTUS (NIRSEVIMAB) APPROVED IN EU | View Document |
| 6-K | Nov. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 26, 2022 | CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS | View Document |
| 6-K | Oct. 25, 2022 | UPDATE ON MESSINA PHASE III TRIAL | View Document |
| 6-K | Oct. 24, 2022 | IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER | View Document |
| 6-K | Oct. 3, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 30, 2022 | BOARD COMMITTEE CHANGES | View Document |
| 6-K | Sept. 27, 2022 | KOSELUGO APPROVED IN JAPAN FOR NF1 | View Document |
| 6-K | Sept. 27, 2022 | TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA | View Document |
| 6-K | Sept. 23, 2022 | ULTOMIRIS APPROVED IN EU FOR GMG | View Document |
| 6-K | Sept. 22, 2022 | LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER | View Document |
| 6-K | Sept. 21, 2022 | TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA | View Document |
| 6-K | Sept. 20, 2022 | EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT | View Document |
| 6-K | Sept. 16, 2022 | DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Sept. 16, 2022 | NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP | View Document |
| 6-K | Sept. 16, 2022 | EVUSHELD POSITIVE CHMP OPINION IN EU | View Document |
| 6-K | Sept. 6, 2022 | FORXIGA APPROVED IN CHINA FOR CKD | View Document |
| 6-K | Sept. 6, 2022 | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER | View Document |
| 6-K | Sept. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 30, 2022 | EVUSHELD APPROVED FOR COVID-19 IN JAPAN | View Document |
| 6-K | Aug. 30, 2022 | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE | View Document |
| 6-K | Aug. 30, 2022 | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF | View Document |
| 6-K | Aug. 25, 2022 | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER | View Document |
| 6-K | Aug. 25, 2022 | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER | View Document |
| 6-K | Aug. 25, 2022 | ULTOMIRIS APPROVED IN JAPAN FOR GMG | View Document |
| 6-K | Aug. 16, 2022 | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL | View Document |
| 6-K | Aug. 15, 2022 | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 | View Document |
| 6-K | Aug. 12, 2022 | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC | View Document |
| 6-K | Aug. 11, 2022 | ACQUISITION OF TENEOTWO COMPLETED | View Document |
| 6-K | Aug. 8, 2022 | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC | View Document |
| 6-K | Aug. 4, 2022 | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER | View Document |
| 6-K | Aug. 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 29, 2022 | CHAIR SUCCESSION | View Document |
| 6-K | July 29, 2022 | FORM 6-K | View Document |
| 6-K | July 25, 2022 | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA | View Document |
| 6-K | July 25, 2022 | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG | View Document |
| 6-K | July 25, 2022 | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC | View Document |
| 6-K | July 19, 2022 | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC | View Document |
| SC 13G | July 8, 2022 | - | View Document |
| 6-K | July 5, 2022 | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER | View Document |
| 6-K | July 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 30, 2022 | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER | View Document |
| 11-K | June 29, 2022 | ANNUAL REPORT | View Document |
| 6-K | June 27, 2022 | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL | View Document |
| 6-K | June 27, 2022 | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER | View Document |
| 6-K | June 21, 2022 | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS | View Document |
| 25-NSE | June 10, 2022 | - | View Document |
| 25-NSE | June 9, 2022 | - | View Document |
| 6-K | June 6, 2022 | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER | View Document |
| 6-K | June 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 1, 2022 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 20, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 9, 2022 | APPOINTMENT OF JOINT CORPORATE BROKERS | View Document |
| 6-K | May 6, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 5, 2022 | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER | View Document |
| 6-K | May 5, 2022 | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | May 5, 2022 | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | May 4, 2022 | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC | View Document |
| 6-K | May 3, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 29, 2022 | FIRST QUARTER 2022 RESULTS | View Document |
| 6-K | April 29, 2022 | RESULT OF AGM | View Document |
| 6-K | April 29, 2022 | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS | View Document |
| 6-K | April 28, 2022 | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG | View Document |
| 6-K | April 27, 2022 | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER | View Document |
| 6-K | April 25, 2022 | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | View Document |
| 6-K | April 19, 2022 | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | View Document |
| 6-K | April 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 29, 2022 | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | View Document |
| 6-K | March 28, 2022 | EVUSHELD APPROVED IN THE EU FOR COVID-19 | View Document |
| 6-K | March 25, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 24, 2022 | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | View Document |
| 6-K | March 24, 2022 | EVUSHELD POSITIVE EU CHMP OPINION | View Document |
| 6-K | March 23, 2022 | NOTICE OF AGM | View Document |
| 6-K | March 23, 2022 | FORM 6-K | View Document |
| 6-K | March 17, 2022 | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | View Document |
| 6-K | March 14, 2022 | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | View Document |
| 6-K | March 14, 2022 | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | View Document |
| 6-K | March 9, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 7, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 1, 2022 | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | View Document |
| 6-K | Feb. 23, 2022 | FILING OF FORM 20-F WITH SEC | View Document |
| IRANNOTICE | Feb. 22, 2022 | IRANNOTICE | View Document |
| 20-F | Feb. 22, 2022 | FORM 20F | View Document |
| 6-K | Feb. 22, 2022 | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT | View Document |
| 6-K | Feb. 22, 2022 | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | View Document |
| 6-K | Feb. 16, 2022 | SAPHNELO APPROVED IN EU FOR SLE | View Document |
| 6-K | Feb. 15, 2022 | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE | View Document |
| 6-K | Feb. 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 10, 2022 | AZN: FULL YEAR AND Q4 2021 RESULTS | View Document |
| SC 13G/A | Feb. 7, 2022 | - | View Document |
| SC 13G/A | Feb. 4, 2022 | SEC SCHEDULE 13G | View Document |
| 6-K | Feb. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 19, 2022 | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER | View Document |
| 6-K | Jan. 19, 2022 | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC | View Document |
| 6-K | Jan. 18, 2022 | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER | View Document |
| 6-K | Jan. 7, 2022 | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 | View Document |
| 6-K | Jan. 5, 2022 | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED | View Document |
| 6-K | Jan. 4, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 29, 2021 | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL | View Document |
| 6-K | Dec. 21, 2021 | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG | View Document |
| 6-K | Dec. 20, 2021 | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE | View Document |
| 6-K | Dec. 20, 2021 | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA | View Document |
| 6-K | Dec. 15, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 9, 2021 | EVUSHELD US FDA EUA | View Document |
| 6-K | Dec. 7, 2021 | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN | View Document |
| 6-K | Dec. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 1, 2021 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 30, 2021 | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA | View Document |
| 6-K | Nov. 15, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 12, 2021 | AZN: YEAR TO DATE AND Q3 2021 RESULTS | View Document |
| 6-K | Nov. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 1, 2021 | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR | View Document |
| 6-K | Oct. 25, 2021 | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER | View Document |
| 6-K | Oct. 18, 2021 | AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER | View Document |
| 6-K | Oct. 15, 2021 | IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER | View Document |
| 6-K | Oct. 12, 2021 | AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS | View Document |
| 6-K | Oct. 4, 2021 | ENHERTU GRANTED BTD FOR BREAST CANCER | View Document |
| 6-K | Oct. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 30, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 29, 2021 | ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES | View Document |
| 6-K | Sept. 28, 2021 | SAPHNELO APPROVED IN JAPAN FOR SLE | View Document |
| 6-K | Sept. 24, 2021 | LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT | View Document |
| 6-K | Sept. 23, 2021 | BOARD COMMITTEE CHANGE | View Document |
| 6-K | Sept. 23, 2021 | NEW SUSTAINABILITY COMMITTEE OF THE BOARD | View Document |
| 6-K | Sept. 21, 2021 | ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT | View Document |
| 6-K | Sept. 20, 2021 | ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% | View Document |
| 6-K | Sept. 9, 2021 | IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON | View Document |
| 6-K | Sept. 9, 2021 | FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC | View Document |
| 6-K | Sept. 3, 2021 | ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH | View Document |
| 6-K | Sept. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 26, 2021 | FORXIGA APPROVED IN JAPAN FOR CKD | View Document |
| 6-K | Aug. 26, 2021 | ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT | View Document |
| 6-K | Aug. 20, 2021 | AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Aug. 20, 2021 | UPDATE ON ULTOMIRIS PHASE III ALS TRIAL | View Document |
| 6-K | Aug. 16, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 11, 2021 | UPDATE ON US REVIEW OF ROXADUSTAT | View Document |
| 6-K | Aug. 9, 2021 | FORXIGA APPROVED IN THE EU FOR CKD | View Document |
| 6-K | Aug. 9, 2021 | ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT | View Document |
| 6-K | Aug. 2, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 2, 2021 | SAPHNELO APPROVED IN THE US FOR SLE | View Document |
| 6-K/A | July 30, 2021 | FORM 6-K/A | View Document |
| 6-K | July 30, 2021 | FORM 6-K | View Document |
| 6-K | July 26, 2021 | ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH | View Document |
| 6-K | July 22, 2021 | DIRECTORATE CHANGE | View Document |
| 6-K | July 21, 2021 | FORM 6-K | View Document |
| 6-K | July 21, 2021 | ACQUISITION OF ALEXION COMPLETED | View Document |
| 6-K | July 21, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 21, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| F-6EF | July 19, 2021 | REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES | View Document |
| 6-K | July 19, 2021 | IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC | View Document |
| 6-K | July 16, 2021 | STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT | View Document |
| 425 | July 14, 2021 | 425 | View Document |
| 6-K | July 14, 2021 | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK | View Document |
| 425 | July 14, 2021 | 425 | View Document |
| 6-K | July 8, 2021 | TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA | View Document |
| 6-K | July 6, 2021 | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU | View Document |
| 425 | July 6, 2021 | 425 | View Document |
| 425 | July 6, 2021 | 425 | View Document |
| 6-K | July 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 425 | June 30, 2021 | 425 | View Document |
| 11-K | June 29, 2021 | FORM 11-K | View Document |
| 6-K | June 28, 2021 | NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE | View Document |
| 6-K | June 28, 2021 | FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD | View Document |
| 6-K | June 24, 2021 | LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER | View Document |
| 6-K | June 23, 2021 | ORPATHYS APPROVED IN CHINA FOR LUNG CANCER | View Document |
| 6-K | June 22, 2021 | KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 | View Document |
| 6-K | June 15, 2021 | UPDATE ON AZD7442 STORM CHASER TRIAL | View Document |
| 6-K | June 7, 2021 | CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB | View Document |
| 425 | June 4, 2021 | 425 | View Document |
| 6-K | June 4, 2021 | ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER | View Document |
| 6-K | June 4, 2021 | LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER | View Document |
| 425 | June 4, 2021 | 425 | View Document |
| CERT | June 3, 2021 | - | View Document |
| 6-K | June 2, 2021 | PUBLICATION OF FINAL TERMS | View Document |
| 6-K | June 1, 2021 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | June 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 8-A12B | June 1, 2021 | 8-A12B | View Document |
| 6-K | May 28, 2021 | TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG | View Document |
| 6-K | May 28, 2021 | FORM 6-K | View Document |
| 6-K | May 27, 2021 | ASTRAZENECA PRICES A EUR800M BOND OFFERING | View Document |
| 424B2 | May 27, 2021 | 424B2 | View Document |
| 425 | May 27, 2021 | 425 | View Document |
| FWP | May 26, 2021 | FWP | View Document |
| 6-K | May 26, 2021 | ASTRAZENECA PRICES A $7BN BOND OFFERING | View Document |
| 6-K | May 26, 2021 | FORM 6-K | View Document |
| FWP | May 26, 2021 | FWP | View Document |
| 6-K | May 25, 2021 | EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS | View Document |
| 424B2 | May 24, 2021 | 424B2 | View Document |
| 6-K | May 24, 2021 | FORM 6-K | View Document |
| F-3ASR | May 24, 2021 | F-3ASR | View Document |
| 425 | May 24, 2021 | 425 | View Document |
| 6-K | May 21, 2021 | ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN | View Document |
| 6-K | May 18, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 11, 2021 | RESULT OF AGM | View Document |
| 6-K | May 11, 2021 | SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION | View Document |
| 425 | May 7, 2021 | 425 | View Document |
| 6-K | May 7, 2021 | IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON | View Document |
| 425 | May 6, 2021 | 425 | View Document |
| 425 | May 5, 2021 | 425 | View Document |
| 6-K | May 4, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 4, 2021 | FARXIGA APPROVED IN THE US FOR CKD | View Document |
| 425 | April 30, 2021 | 425 | View Document |
| 425 | April 30, 2021 | 425 | View Document |
| 425 | April 30, 2021 | 425 | View Document |
| 6-K | April 30, 2021 | AZN: FIRST QUARTER 2021 RESULTS | View Document |
| 425 | April 29, 2021 | 425 | View Document |
| 6-K | April 26, 2021 | TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION | View Document |
| 6-K | April 26, 2021 | SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 | View Document |
| 6-K | April 26, 2021 | NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 425 | April 16, 2021 | 425 | View Document |
| 6-K | April 16, 2021 | US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION | View Document |
| 425 | April 16, 2021 | 425 | View Document |
| 6-K | April 14, 2021 | TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER | View Document |
| 424B3 | April 13, 2021 | 424B3 | View Document |
| 425 | April 12, 2021 | 425 | View Document |
| 6-K | April 12, 2021 | FORM 6-K | View Document |
| 6-K | April 12, 2021 | CIRCULAR AND NOTICE OF GENERAL MEETING | View Document |
| 425 | April 12, 2021 | 425 | View Document |
| 6-K | April 12, 2021 | UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL | View Document |
| EFFECT | April 12, 2021 | - | View Document |
| F-4/A | April 9, 2021 | F-4/A | View Document |
| CORRESP | April 8, 2021 | - | View Document |
| 425 | April 1, 2021 | 425 | View Document |
| 425 | April 1, 2021 | 425 | View Document |
| 6-K | April 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 425 | April 1, 2021 | 425 | View Document |
| 6-K | March 30, 2021 | FORM 6-K | View Document |
| 6-K | March 30, 2021 | NOTICE OF AGM | View Document |
| 6-K | March 25, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 25, 2021 | AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY | View Document |
| 6-K | March 22, 2021 | ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT | View Document |
| 4 | March 16, 2021 | 4 | View Document |
| 6-K | March 16, 2021 | DIVESTMENT OF VIELA SHAREHOLDING COMPLETED | View Document |
| 6-K | March 16, 2021 | US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES | View Document |
| 425 | March 12, 2021 | 425 | View Document |
| 6-K | March 9, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 4, 2021 | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES | View Document |
| 6-K | March 3, 2021 | US COURT DECISION FAVOURS SYMBICORT PATENTS | View Document |
| 6-K | March 2, 2021 | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE | View Document |
| 6-K | March 1, 2021 | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL | View Document |
| UPLOAD | March 1, 2021 | - | View Document |
| 425 | Feb. 26, 2021 | 425 | View Document |
| 425 | Feb. 25, 2021 | 425 | View Document |
| 6-K | Feb. 22, 2021 | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | View Document |
| F-4 | Feb. 19, 2021 | F-4 | View Document |
| 6-K | Feb. 17, 2021 | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | View Document |
| IRANNOTICE | Feb. 16, 2021 | IRANNOTICE | View Document |
| 6-K | Feb. 16, 2021 | FILING OF FORM 20-F WITH SEC | View Document |
| 6-K | Feb. 16, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 16, 2021 | ANNUAL FINANCIAL REPORT | View Document |
| 20-F | Feb. 16, 2021 | 20-F | View Document |
| 425 | Feb. 12, 2021 | 425 | View Document |
| 425 | Feb. 11, 2021 | 425 | View Document |
| 425 | Feb. 11, 2021 | 425 | View Document |
| 425 | Feb. 11, 2021 | 425 | View Document |
| 6-K | Feb. 11, 2021 | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES | View Document |
| 425 | Feb. 11, 2021 | 425 | View Document |
| 6-K | Feb. 11, 2021 | AZN: FULL-YEAR 2020 RESULTS | View Document |
| 6-K | Feb. 10, 2021 | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED | View Document |
| 6-K | Feb. 5, 2021 | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI | View Document |
| 6-K | Feb. 4, 2021 | FORXIGA APPROVED IN CHINA FOR HEART FAILURE | View Document |
| SC 13G/A | Feb. 3, 2021 | SEC SCHEDULE 13G | View Document |
| 6-K | Feb. 1, 2021 | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU | View Document |
| 6-K | Feb. 1, 2021 | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING | View Document |
| 6-K | Feb. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| SC 13G/A | Jan. 29, 2021 | - | View Document |
| 6-K | Jan. 29, 2021 | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU | View Document |
| 6-K | Jan. 26, 2021 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Jan. 26, 2021 | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA | View Document |
| 6-K | Jan. 25, 2021 | CALQUENCE APPROVED IN JAPAN FOR CLL | View Document |
| 6-K | Jan. 25, 2021 | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB | View Document |
| 6-K | Jan. 20, 2021 | ENHERTU APPROVED IN THE EU FOR BREAST CANCER | View Document |
| 6-K | Jan. 19, 2021 | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER | View Document |
| 6-K | Jan. 15, 2021 | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO | View Document |
| 6-K | Jan. 6, 2021 | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR | View Document |
| 6-K | Jan. 4, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 4, 2021 | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED | View Document |
| 6-K | Dec. 30, 2020 | ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK | View Document |
| 6-K | Dec. 29, 2020 | LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P | View Document |
| 6-K | Dec. 21, 2020 | UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS | View Document |
| 6-K | Dec. 21, 2020 | TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST | View Document |
| 425 | Dec. 18, 2020 | 425 | View Document |
| 425 | Dec. 17, 2020 | 425 | View Document |
| 6-K | Dec. 17, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 16, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 15, 2020 | IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION | View Document |
| 425 | Dec. 15, 2020 | 425 | View Document |
| 425 | Dec. 14, 2020 | 425 | View Document |
| 425 | Dec. 14, 2020 | 425 | View Document |
| 425 | Dec. 14, 2020 | 425 | View Document |
| 6-K | Dec. 14, 2020 | TRASTUZUMAB DERUXTECAN POSITIVE CHMP | View Document |
| 6-K | Dec. 14, 2020 | TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD | View Document |
| 6-K | Dec. 14, 2020 | ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC | View Document |
| 425 | Dec. 14, 2020 | 425 | View Document |
| 6-K | Dec. 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 1, 2020 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 1, 2020 | CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE | View Document |
| 6-K | Nov. 30, 2020 | FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE | View Document |
| 6-K | Nov. 23, 2020 | AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 | View Document |
| 6-K | Nov. 20, 2020 | IMFINZI NEW DOSING APPROVED IN THE US | View Document |
| 25-NSE | Nov. 13, 2020 | - | View Document |
| 6-K | Nov. 10, 2020 | TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Nov. 9, 2020 | CALQUENCE APPROVED IN THE EU FOR CLL | View Document |
| 6-K | Nov. 6, 2020 | BRILINTA APPROVED IN THE US IN STROKE | View Document |
| 6-K | Nov. 5, 2020 | FORXIGA APPROVED IN THE EU FOR HEART FAILURE | View Document |
| 6-K | Nov. 5, 2020 | AZN: YEAR-TO-DATE AND Q3 2020 RESULTS | View Document |
| 6-K | Nov. 5, 2020 | LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | View Document |
| 6-K | Nov. 5, 2020 | LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT | View Document |
| 6-K | Nov. 2, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 30, 2020 | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES | View Document |
| 6-K | Oct. 29, 2020 | DIRECTORATE CHANGE | View Document |
| 6-K | Oct. 28, 2020 | FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA | View Document |
| 6-K | Oct. 28, 2020 | ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET | View Document |
| 6-K | Oct. 20, 2020 | TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW | View Document |
| 6-K | Oct. 19, 2020 | FORXIGA HF RECEIVES POSITIVE CHMP OPINION | View Document |
| 6-K | Oct. 19, 2020 | TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION | View Document |
| 6-K | Oct. 13, 2020 | COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING | View Document |
| 6-K | Oct. 2, 2020 | FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE | View Document |
| 6-K | Oct. 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 25, 2020 | DIRECTORATE CHANGE | View Document |
| 25 | Sept. 24, 2020 | 25 | View Document |
| CERT | Sept. 24, 2020 | - | View Document |
| 8-A12B | Sept. 24, 2020 | 8-A12B | View Document |
| 6-K | Sept. 21, 2020 | LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC | View Document |
| 6-K | Sept. 21, 2020 | LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT | View Document |
| 6-K | Sept. 21, 2020 | TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV | View Document |
| 6-K | Sept. 10, 2020 | ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ | View Document |
| 6-K | Sept. 10, 2020 | FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I | View Document |
| 6-K | Sept. 1, 2020 | IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER | View Document |
| 6-K | Sept. 1, 2020 | FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH | View Document |
| 6-K | Sept. 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 25, 2020 | PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE | View Document |
| 6-K | Aug. 21, 2020 | IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C | View Document |
| 6-K | Aug. 18, 2020 | IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE | View Document |
| CERT | Aug. 12, 2020 | NYSE CERTIFICATION | View Document |
| 6-K | Aug. 6, 2020 | FORM 6-K | View Document |
| 8-A12B | Aug. 6, 2020 | FORM 8-A12B | View Document |
| 424B2 | Aug. 5, 2020 | FORM 424B2 | View Document |
| 6-K | Aug. 4, 2020 | ASTRAZENECA PRICES A $3BN BOND ISSUE | View Document |
| FWP | Aug. 4, 2020 | FORM FWP | View Document |
| 424B2 | Aug. 3, 2020 | FORM 424B2 | View Document |
| S-8 | Aug. 3, 2020 | S-8 | View Document |
| 6-K | Aug. 3, 2020 | TOTAL VOTING RIGHTS | View Document |
| FWP | Aug. 3, 2020 | FORM FWP | View Document |
| 6-K/A | July 31, 2020 | 6-K/A | View Document |
| 6-K | July 30, 2020 | AZN: H1 2020 RESULTS | View Document |
| 6-K | July 30, 2020 | TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER | View Document |
| 6-K | July 29, 2020 | BOARD COMMITTEE CHANGES | View Document |
| 6-K | July 28, 2020 | FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS | View Document |
| 6-K | July 27, 2020 | ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY | View Document |
| 6-K | July 27, 2020 | IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC | View Document |
| 6-K | July 27, 2020 | CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL | View Document |
| 6-K | July 24, 2020 | BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD | View Document |
| 6-K | July 22, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 22, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 21, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 21, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 20, 2020 | COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P | View Document |
| 6-K | July 16, 2020 | DIRECTOR DECLARATION | View Document |
| 6-K | July 9, 2020 | BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE | View Document |
| 6-K | July 8, 2020 | LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER | View Document |
| 6-K | July 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 30, 2020 | SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE | View Document |
| 6-K | June 30, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 11-K | June 26, 2020 | - | View Document |
| 6-K | June 17, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | June 17, 2020 | HOLDING(S) IN COMPANY | View Document |
| 6-K | June 15, 2020 | ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S | View Document |
| 6-K | June 11, 2020 | EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS | View Document |
| 6-K | June 1, 2020 | LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC | View Document |
| 6-K | June 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 1, 2020 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | June 1, 2020 | BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE | View Document |
| 6-K | May 29, 2020 | TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM | View Document |
| 6-K | May 29, 2020 | ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- | View Document |
| 6-K | May 29, 2020 | IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE | View Document |
| 6-K | May 26, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 22, 2020 | ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER | View Document |
| 6-K | May 21, 2020 | ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST | View Document |
| 6-K | May 20, 2020 | LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT | View Document |
| 6-K | May 18, 2020 | ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER | View Document |
| 6-K | May 18, 2020 | BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD | View Document |
| 6-K | May 11, 2020 | ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM | View Document |
| 6-K | May 11, 2020 | ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET | View Document |
| 6-K | May 11, 2020 | LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | View Document |
| 6-K | May 6, 2020 | FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H | View Document |
| 6-K | May 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 29, 2020 | RESULT OF AGM | View Document |
| 6-K | April 29, 2020 | AZN: FIRST-QUARTER 2020 RESULTS | View Document |
| 6-K | April 24, 2020 | LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B | View Document |
| 6-K | April 17, 2020 | CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING | View Document |
| 6-K | April 14, 2020 | TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC | View Document |
| 6-K | April 14, 2020 | KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT | View Document |
| 6-K | April 2, 2020 | ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED | View Document |
| 6-K | April 1, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 31, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 30, 2020 | FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA | View Document |
| 6-K | March 30, 2020 | IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER | View Document |
| 6-K | March 26, 2020 | LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA | View Document |
| 6-K | March 26, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 20, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 19, 2020 | LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA | View Document |
| 6-K | March 17, 2020 | IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE | View Document |
| 6-K | March 12, 2020 | UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS | View Document |
| 6-K | March 12, 2020 | NOTICE OF AGM | View Document |
| 6-K | March 12, 2020 | 6-K | View Document |
| 6-K | March 10, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2020 | UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S | View Document |
| 6-K | March 4, 2020 | FILING OF FORM 20-F WITH SEC | View Document |
| IRANNOTICE | March 3, 2020 | IRANNOTICE | View Document |
| 20-F | March 3, 2020 | 20-F | View Document |
| 6-K | March 3, 2020 | ANNUAL FINANCIAL REPORT | View Document |
| 6-K | March 2, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 2, 2020 | ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY | View Document |
| 6-K | Feb. 27, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 25, 2020 | ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK | View Document |
| 6-K | Feb. 19, 2020 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 14, 2020 | AZN: FULL-YEAR AND Q4 2019 RESULTS | View Document |
| 4 | Feb. 7, 2020 | 4 | View Document |
| 3 | Feb. 7, 2020 | 3 | View Document |
| SC 13D | Feb. 7, 2020 | SC 13D | View Document |
| EFFECT | Feb. 6, 2020 | - | View Document |
| SC 13G/A | Feb. 5, 2020 | - | View Document |
| 6-K | Feb. 3, 2020 | TOTAL VOTING RIGHTS | View Document |
| SC 13G | Jan. 30, 2020 | SC 13G | View Document |
| SC 13G/A | Jan. 27, 2020 | SEC SCHEDULE 13G | View Document |
| 6-K | Jan. 27, 2020 | PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP | View Document |
| 6-K | Jan. 27, 2020 | ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN | View Document |
| 6-K | Jan. 27, 2020 | BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE | View Document |
| 6-K | Jan. 27, 2020 | ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES | View Document |
| F-6 | Jan. 22, 2020 | FORM F-6 | View Document |
| 6-K | Jan. 21, 2020 | IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN | View Document |
| 6-K | Jan. 21, 2020 | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED | View Document |
| 6-K | Jan. 13, 2020 | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA | View Document |
| 6-K | Jan. 13, 2020 | UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA | View Document |
| 6-K | Jan. 6, 2020 | LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA | View Document |
| 6-K | Jan. 6, 2020 | FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED | View Document |
| 6-K | Jan. 2, 2020 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 30, 2019 | LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- | View Document |
| 6-K | Dec. 23, 2019 | ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP | View Document |
| 6-K | Dec. 23, 2019 | ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB | View Document |
| 6-K | Dec. 20, 2019 | ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO | View Document |
| 6-K | Dec. 17, 2019 | FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER | View Document |
| 6-K | Dec. 16, 2019 | SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA | View Document |
| 6-K | Dec. 12, 2019 | IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL | View Document |
| 6-K | Dec. 11, 2019 | TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE | View Document |
| 6-K | Dec. 5, 2019 | LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV | View Document |
| 6-K | Dec. 3, 2019 | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA | View Document |
| 6-K | Dec. 2, 2019 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 2, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 29, 2019 | IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE | View Document |
| 6-K | Nov. 21, 2019 | CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM | View Document |
| 6-K | Nov. 15, 2019 | QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D | View Document |
| 6-K | Nov. 14, 2019 | FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB | View Document |
| 6-K | Nov. 12, 2019 | ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE | View Document |
| 6-K | Nov. 12, 2019 | ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I | View Document |
| 6-K | Nov. 8, 2019 | ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE | View Document |
| F-3ASR | Nov. 8, 2019 | FORM F-3ASR | View Document |
| 6-K | Nov. 6, 2019 | CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN | View Document |
| 6-K | Nov. 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 30, 2019 | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA | View Document |
| 6-K | Oct. 28, 2019 | IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED | View Document |
| 6-K | Oct. 24, 2019 | ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS | View Document |
| 6-K | Oct. 21, 2019 | FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU | View Document |
| 6-K | Oct. 17, 2019 | TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT | View Document |
| 4 | Oct. 9, 2019 | FORM 4 SUBMISSION | View Document |
| 3/A | Oct. 9, 2019 | FORM 3/A SUBMISSION | View Document |
| 6-K | Oct. 4, 2019 | FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION | View Document |
| 6-K | Oct. 4, 2019 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Oct. 4, 2019 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Oct. 3, 2019 | DIRECTOR DECLARATION | View Document |
| 3 | Oct. 2, 2019 | FORM 3 SUBMISSION | View Document |
| 6-K | Oct. 1, 2019 | UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD | View Document |
| 6-K | Oct. 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 1, 2019 | ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR | View Document |
| 6-K | Sept. 30, 2019 | TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN | View Document |
| 6-K | Sept. 30, 2019 | LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN | View Document |
| 6-K | Sept. 30, 2019 | LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS | View Document |
| 6-K | Sept. 23, 2019 | QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP | View Document |
| 25-NSE | Sept. 18, 2019 | - | View Document |
| 6-K | Sept. 18, 2019 | ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA | View Document |
| 6-K | Sept. 9, 2019 | IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP | View Document |
| 6-K | Sept. 4, 2019 | TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE | View Document |
| 6-K | Sept. 3, 2019 | DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC | View Document |
| 6-K | Sept. 3, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 3, 2019 | BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART | View Document |
| 6-K | Aug. 29, 2019 | ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS | View Document |
| 6-K | Aug. 28, 2019 | BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS | View Document |
| 6-K | Aug. 28, 2019 | FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS | View Document |
| 6-K | Aug. 22, 2019 | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND | View Document |
| 6-K | Aug. 22, 2019 | ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW | View Document |
| 6-K | Aug. 21, 2019 | UPDATE ON THE PHASE III NEPTUNE TRIAL | View Document |
| 6-K | Aug. 20, 2019 | FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III | View Document |
| 6-K | Aug. 19, 2019 | DIRECTORATE CHANGE | View Document |
| 6-K | Aug. 14, 2019 | CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 6-K | Aug. 14, 2019 | LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Aug. 9, 2019 | TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL | View Document |
| 6-K | Aug. 7, 2019 | LYNPARZA PHASE III PROFOUND TRIAL IN HRR* | View Document |
| 6-K | Aug. 5, 2019 | FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES | View Document |
| 6-K | Aug. 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 25, 2019 | 6-K | View Document |
| 6-K | July 15, 2019 | UPDATE ON US REGULATORY DECISION FOR FARXIGA | View Document |
| 6-K | July 12, 2019 | IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER | View Document |
| 6-K | July 1, 2019 | FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR | View Document |
| 6-K | July 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 1, 2019 | FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF | View Document |
| 11-K | June 27, 2019 | - | View Document |
| 6-K | June 27, 2019 | IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM | View Document |
| 6-K | June 19, 2019 | BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI | View Document |
| 6-K | June 19, 2019 | BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA | View Document |
| 6-K | June 19, 2019 | LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA | View Document |
| 6-K | June 18, 2019 | LYNPARZA APPROVED IN THE EU FOR 1ST-LINE | View Document |
| 6-K | June 17, 2019 | CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT | View Document |
| 6-K | June 12, 2019 | PUBLICATION OF A PROSPECTUS | View Document |
| 6-K | June 6, 2019 | CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY | View Document |
| 6-K | June 3, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 3, 2019 | LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM | View Document |
| 6-K | June 3, 2019 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 10, 2019 | POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III | View Document |
| 6-K | May 8, 2019 | DIRECTOR DECLARATION | View Document |
| 6-K | May 8, 2019 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 8, 2019 | TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY | View Document |
| 6-K | May 7, 2019 | CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | May 3, 2019 | QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES | View Document |
| 6-K | May 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 1, 2019 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 29, 2019 | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST | View Document |
| 6-K | April 26, 2019 | AZN: Q1 2019 RESULTS | View Document |
| 6-K | April 26, 2019 | RESULT OF AGM | View Document |
| 6-K | April 10, 2019 | LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE | View Document |
| 6-K | April 4, 2019 | HOLDING(S) IN COMPANY | View Document |
| 6-K | April 3, 2019 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 2, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 1, 2019 | SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 6-K | March 29, 2019 | AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL | View Document |
| 6-K | March 29, 2019 | RESULTS OF PLACING | View Document |
| 6-K | March 27, 2019 | FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES | View Document |
| 6-K | March 25, 2019 | FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES | View Document |
| 6-K | March 18, 2019 | US FDA GRANTS SARACATINIB ODD FOR IPF | View Document |
| 6-K | March 14, 2019 | NOTICE OF AGM | View Document |
| 6-K | March 14, 2019 | 6-K | View Document |
| 6-K | March 12, 2019 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 6, 2019 | FILING OF FORM 20-F WITH SEC | View Document |
| 20-F | March 5, 2019 | 20-F | View Document |
| IRANNOTICE | March 5, 2019 | IRANNOTICE | View Document |
| 6-K | March 5, 2019 | ANNUAL FINANCIAL REPORT | View Document |
| 6-K | March 1, 2019 | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION | View Document |
| 6-K | March 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 26, 2019 | LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION | View Document |
| 6-K | Feb. 25, 2019 | BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT | View Document |
| 6-K | Feb. 14, 2019 | ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS | View Document |
| SC 13G/A | Feb. 12, 2019 | SEC SCHEDULE 13G | View Document |
| 6-K | Feb. 6, 2019 | US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION | View Document |
| 6-K | Feb. 5, 2019 | EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 | View Document |
| 6-K | Feb. 5, 2019 | US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION | View Document |
| SC 13G/A | Feb. 4, 2019 | - | View Document |
| 6-K | Feb. 1, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 1, 2019 | FORXIGA RECEIVES POSITIVE EU CHMP OPINION | View Document |
| SC 13G | Jan. 30, 2019 | SC 13G | View Document |
| 6-K | Jan. 25, 2019 | COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS | View Document |
| 6-K | Jan. 7, 2019 | ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES | View Document |
| 6-K | Jan. 2, 2019 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 20, 2018 | BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD | View Document |
| 6-K | Dec. 20, 2018 | LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL | View Document |
| 6-K | Dec. 20, 2018 | PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS | View Document |
| 6-K | Dec. 19, 2018 | FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY | View Document |
| 6-K | Dec. 18, 2018 | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE | View Document |
| 6-K | Dec. 14, 2018 | DIRECTORATE CHANGE | View Document |
| 6-K | Dec. 7, 2018 | UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI | View Document |
| 6-K | Dec. 6, 2018 | DIVESTMENT OF RIGHTS TO COVIS COMPLETED | View Document |
| 6-K | Dec. 4, 2018 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 3, 2018 | GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED | View Document |
| 6-K | Dec. 3, 2018 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Dec. 3, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 26, 2018 | US FDA GRANTS FASENRA ODD FOR EGPA | View Document |
| 25-NSE | Nov. 16, 2018 | - | View Document |
| 25-NSE | Nov. 16, 2018 | - | View Document |
| 6-K | Nov. 16, 2018 | ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC | View Document |
| 6-K | Nov. 13, 2018 | FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR | View Document |
| 6-K | Nov. 13, 2018 | ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI | View Document |
| 6-K | Nov. 13, 2018 | US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA | View Document |
| 6-K | Nov. 8, 2018 | AZN: YEAR-TO-DATE AND Q3 2018 RESULTS | View Document |
| 6-K | Nov. 6, 2018 | DIVESTMENT OF RIGHTS TO COVIS PHARMA | View Document |
| 6-K | Nov. 1, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 31, 2018 | ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL | View Document |
| 6-K | Oct. 30, 2018 | GRUNENTHAL AGREEMENT FOR RIGHTS TO NEXIUM VIMOVO | View Document |
| SC 13D | Oct. 29, 2018 | SC 13D | View Document |
| 4 | Oct. 24, 2018 | FORM 4 SUBMISSION | View Document |
| 6-K | Oct. 23, 2018 | ASTRAZENECA EXTENDS INNATE PHARMA COLLABORATION | View Document |
| 6-K | Oct. 22, 2018 | LYNPARZA SHOWS 70% REDUCTION IN PFS OVARIAN CANCER | View Document |
| 6-K | Oct. 19, 2018 | CHMP POSITIVE OPINION BEVESPI AEROSPHERE | View Document |
| 3 | Oct. 17, 2018 | FORM 3 SUBMISSION | View Document |
| 6-K | Oct. 16, 2018 | FDA ORPHAN DRUG FOR LYNPARZA IN PANCREATIC CANCER | View Document |
| SC 13D/A | Oct. 12, 2018 | SC 13D/A | View Document |
| SC 13D | Oct. 5, 2018 | SC 13D | View Document |
| 4 | Oct. 2, 2018 | FORM 4 SUBMISSION | View Document |
| 6-K | Oct. 1, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 1, 2018 | ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED | View Document |
| 6-K | Sept. 28, 2018 | PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NED | View Document |
| 3 | Sept. 25, 2018 | FORM 3 SUBMISSION | View Document |
| 6-K | Sept. 25, 2018 | OVERALL SURVIVAL DATA FOR IMFINZI: STAGE III NSCLC | View Document |
| 6-K | Sept. 24, 2018 | FARXIGA GETS POSITIVE RESULT IN DECLARE-TIMI 58 | View Document |
| 6-K | Sept. 24, 2018 | EMA APPROVES AZ'S IMFINZI FOR STAGE III NSCLC | View Document |
| 6-K | Sept. 14, 2018 | FDA APPROVES AZS LUMOXITI IN HAIRY CELL LEUKAEMIA | View Document |
| 6-K | Sept. 7, 2018 | TEZEPELUMAB FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 6-K | Sept. 6, 2018 | DIRECTORATE CHANGE | View Document |
| 6-K | Sept. 4, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 31, 2018 | ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE | View Document |
| 6-K | Aug. 30, 2018 | EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES | View Document |
| 6-K | Aug. 23, 2018 | ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE | View Document |
| CERT | Aug. 23, 2018 | NYSE CERTIFICATION - ASTRAZENECA PLC | View Document |
| 6-K | Aug. 21, 2018 | AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC | View Document |
| 8-A12B | Aug. 17, 2018 | FORM 8-A12B | View Document |
| 6-K | Aug. 17, 2018 | FORM 6-K | View Document |
| 424B2 | Aug. 16, 2018 | FORM 424B2 | View Document |
| FWP | Aug. 15, 2018 | FORM FWP | View Document |
| 6-K | Aug. 15, 2018 | ASTRAZENECA PRICES A $3BN BOND ISSUE | View Document |
| 424B2 | Aug. 14, 2018 | FORM 424B2 | View Document |
| FWP | Aug. 14, 2018 | FORM FWP | View Document |
| S-8 | Aug. 14, 2018 | S-8 | View Document |
| 6-K | Aug. 10, 2018 | 6-K | View Document |
| 6-K | Aug. 3, 2018 | EMA GRANTS OD FOR SELUMETINIB IN NF1 | View Document |
| 6-K | Aug. 1, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 27, 2018 | CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC | View Document |
| 6-K | July 26, 2018 | 6-K | View Document |
| 6-K | July 24, 2018 | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE | View Document |
| 6-K | July 18, 2018 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 2, 2018 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 2, 2018 | LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER | View Document |
| 6-K | July 2, 2018 | IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC | View Document |
| 6-K | June 29, 2018 | BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISE | View Document |
| 11-K | June 29, 2018 | - | View Document |